Friday Satellite Symposia
Research, Lymphoid Leukemias, Clinical Practice (Health Services and Quality), CLL, Diseases, Lymphoid Malignancies, Adverse Events, Biological Processes, Measurable Residual Disease
San Diego Ballroom AB
(Marriott Marquis San Diego Marina)
Chair:
Prof. John G. Gribben, MD, DSc, Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London
Disclosures:
Gribben: AstraZeneca: Research Funding; Amgen and Gilead Sciences/Kite: Consultancy.
Speakers:
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute, Harvard Medical School
,
Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center, New York-Presbyterian/Columbia University Medical Center
and
Meghan C. Thompson, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
Davids: Genentech: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Surface Technology: Research Funding; TG Therapeutics: Consultancy, Research Funding; BMS: Consultancy; Novartis: Research Funding; Merck: Consultancy; AstraZeneca: Consultancy, Research Funding; Adaptive Biosciences: Consultancy; Janssen: Consultancy; Genmab: Consultancy; Ascentage Pharma: Consultancy, Research Funding; MEI Pharma: Research Funding; BeiGene: Consultancy; Eli Lilly: Consultancy. Lamanna: AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology, Inc.; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc: Research Funding; AbbVie; Adaptive Biotechnologies; Allogene Therapeutics; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC: Consultancy. Thompson: AbbVie: Consultancy, Research Funding; Clinical Care Options: Honoraria; Dava Oncology: Honoraria, Other: Reimbursed travel; AstraZeneca: Consultancy, Research Funding; Peerview Institute for Medical Education: Honoraria; Loxo Oncology at Lilly: Consultancy; BeiGene: Consultancy, Research Funding; Mashup Media LLC: Honoraria, Other: Reimbursed Travel; Nurix Therapeutics: Other: Reimbursed travel, Research Funding; Genentech: Research Funding; Genmab: Other: Reimbursed travel, Research Funding; Pharmacyclics/Janssen Pharmaceuticals: Consultancy; eScientiq: Honoraria; Adaptive Biotechnologies: Research Funding.
This CME/MOC/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, CLL Society.
This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.
In collaboration with CLL Society, PeerView’s unique Clinical Consults event will provide useful information and practical instruction in an engaging, interactive manner designed to explore the rapid transformation of modern CLL therapy. Expert conversations on treatment choices will be paired with practically-oriented case discussions to provide learners with guidance on addressing common clinical challenges arising from the upfront and sequential management of CLL to strategies for integrating emerging, innovative modalities into care. Throughout, the experts will cover:
- Evidence supporting the personalized selection of continuous SOC BTKi or finite 1L regimens;
- The ongoing experience with BTKi-BCL2i combinations;
- Sequential therapy with ncBTKi options and CAR-T immunotherapy in R/R disease;
- Newer modalities such as emerging ncBTKi, next-gen BCL2i, BTK degraders, dual c/ncBTKi, and bispecific antibodies in challenging pre-treated and double-exposed populations.
Don’t miss this opportunity to upgrade your skills in customizing CLL care!
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.